Defined as low blood sugar, the risk may increase when these drugs are used in combination with other diabetes medications like insulin or sulfonylureas
Discussion Using data from the STEP 1 and STEP 2 phase 3 trials, we found broad effects from subcutaneous semaglutide treatment in people with overweight or obesity (with and without T2D) on the circulating proteome compared with placebo
Table 2 Baseline characteristics of CVOTs involving GLP-1 receptor agonists and key findings
A dual-receptor design Tirzepatide activates both the GIP and GLP-1 receptors, combining two hormone pathways instead of relying on one
Headaches, body aches, and other symptoms Headaches during the first weeks are often related to dehydration or blood sugar fluctuations rather than direct medication effects
Ozempic's reduced price available via NovoCare Pharmacy, GoodRx and Novo Nordisk's site